Latest Insider Transactions at Jasper Therapeutics, Inc. (JSPR)
This section provides a real-time view of insider transactions for Jasper Therapeutics, Inc. (JSPR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Jasper Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Jasper Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2024
|
Jeetinder Singh Mahal Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
900
-3.47%
|
$18,900
$21.23 P/Share
|
|
Sep 12
2024
|
Jeetinder Singh Mahal Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+3.36%
|
$6,300
$7.1 P/Share
|
|
Jun 12
2024
|
Jeetinder Singh Mahal Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
900
-3.47%
|
$21,600
$24.16 P/Share
|
|
Jun 12
2024
|
Jeetinder Singh Mahal Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+3.36%
|
$6,300
$7.1 P/Share
|
|
Jun 07
2024
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400
+50.0%
|
$1,600
$4.17 P/Share
|
|
Mar 12
2024
|
Jeetinder Singh Mahal Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
900
-3.47%
|
$23,400
$26.44 P/Share
|
|
Mar 12
2024
|
Jeetinder Singh Mahal Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+3.36%
|
$6,300
$7.1 P/Share
|
|
Feb 08
2024
|
Carlyle Group Inc. |
BUY
Open market or private purchase
|
Indirect |
190,000
+15.13%
|
$2,280,000
$12.95 P/Share
|
|
Feb 08
2024
|
Velan Capital Investment Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
350,000
+22.75%
|
$4,200,000
$12.95 P/Share
|
|
Nov 28
2023
|
Thomas G Wiggans Director |
BUY
Open market or private purchase
|
Direct |
10,000
+16.67%
|
$0
$0.65 P/Share
|
|
Nov 21
2023
|
Thomas G Wiggans Director |
BUY
Open market or private purchase
|
Direct |
10,000
+20.0%
|
$0
$0.64 P/Share
|
|
Nov 20
2023
|
Thomas G Wiggans Director |
BUY
Open market or private purchase
|
Direct |
10,000
+25.0%
|
$0
$0.63 P/Share
|
|
Nov 17
2023
|
Thomas G Wiggans Director |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$0
$0.6 P/Share
|
|
Nov 16
2023
|
Thomas G Wiggans Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$0
$0.6 P/Share
|
|
Oct 13
2023
|
William Lis Director |
SELL
Open market or private sale
|
Direct |
7,965
-12.95%
|
$0
$0.85 P/Share
|
|
Oct 12
2023
|
Ron Martell President, CEO and Director |
SELL
Payment of exercise price or tax liability
|
Direct |
87,531
-20.9%
|
$0
$0.85 P/Share
|
|
Oct 12
2023
|
Jeetinder Singh Mahal Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,126
-12.93%
|
$0
$0.85 P/Share
|
|
Jun 13
2023
|
Jeetinder Singh Mahal Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,000
-3.04%
|
$9,000
$1.66 P/Share
|
|
Jun 13
2023
|
Jeetinder Singh Mahal Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+2.95%
|
$0
$0.71 P/Share
|
|
Apr 14
2023
|
Anna Louise French Director |
SELL
Open market or private sale
|
Direct |
7,000
-22.76%
|
$7,000
$1.48 P/Share
|
|
Apr 13
2023
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Direct |
9,075
-30.0%
|
$9,075
$1.49 P/Share
|
|
Apr 13
2023
|
William Lis Director |
SELL
Open market or private sale
|
Direct |
8,500
-12.15%
|
$8,500
$1.44 P/Share
|
|
Apr 12
2023
|
Jeetinder Singh Mahal Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,126
-11.45%
|
$37,126
$1.46 P/Share
|
|
Apr 12
2023
|
Ron Martell President, CEO and Director |
SELL
Payment of exercise price or tax liability
|
Direct |
87,531
-17.29%
|
$87,531
$1.46 P/Share
|
|
Jan 27
2023
|
Qiming U.S. Healthcare Fund Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
2,666,666
+23.84%
|
$2,666,666
$1.5 P/Share
|
|
Jan 27
2023
|
Carlyle Group Inc. |
BUY
Open market or private purchase
|
Indirect |
3,133,333
+26.34%
|
$3,133,333
$1.5 P/Share
|
|
Jan 25
2023
|
Roche Holding LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
75,000
-1.62%
|
$75,000
$1.89 P/Share
|
|
Oct 12
2022
|
Ron Martell President, CEO and Director |
BUY
Grant, award, or other acquisition
|
Direct |
506,250
+50.0%
|
-
|
|
Oct 12
2022
|
Lawrence Otto Klein Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,500
+50.0%
|
-
|
|
Oct 12
2022
|
Judith Anne Shizuru Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,500
+2.48%
|
-
|
|
Oct 12
2022
|
Jeetinder Singh Mahal Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
214,722
+39.83%
|
-
|
|
Oct 12
2022
|
Chris Nolet Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+50.0%
|
-
|
|
Oct 12
2022
|
William Lis Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,500
+29.65%
|
-
|
|
Oct 12
2022
|
Anna Louise French Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,750
+50.0%
|
-
|
|
Oct 12
2022
|
Kurt Von Emster Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,250
+50.0%
|
-
|
|
Jun 27
2022
|
William Lis Director |
SELL
Open market or private sale
|
Direct |
24,743
-37.93%
|
$49,486
$2.08 P/Share
|
|
Jun 24
2022
|
William Lis Director |
SELL
Open market or private sale
|
Direct |
24,743
-27.5%
|
$49,486
$2.02 P/Share
|
|
Mar 21
2022
|
William Lis Director |
BUY
Grant, award, or other acquisition
|
Direct |
89,972
+50.0%
|
-
|
|
Sep 24
2021
|
Amplitude Healthcare Holdings LLC > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
2,300,000
+50.0%
|
-
|
|
Sep 24
2021
|
Balaji Venkataraman |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,300,000
+50.0%
|
-
|
|
Sep 24
2021
|
Howard I Hoffen |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,300,000
+50.0%
|
-
|
|
Sep 24
2021
|
Kenneth F Clifford |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,300,000
+50.0%
|
-
|
|
Apr 23
2021
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
151,719
-14.49%
|
$1,365,471
$9.92 P/Share
|
|
Apr 21
2021
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,164
-0.11%
|
$10,476
$9.92 P/Share
|
|
Apr 19
2021
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,060
-0.2%
|
$18,540
$9.97 P/Share
|
|
Feb 22
2021
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
698
-0.07%
|
$6,980
$10.5 P/Share
|
|
Feb 19
2021
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,112
-0.2%
|
$21,120
$10.5 P/Share
|
|
Feb 18
2021
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-0.94%
|
$100,000
$10.45 P/Share
|
|
Feb 05
2021
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
212
-0.02%
|
$2,120
$10.4 P/Share
|
|
Jan 14
2021
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
101
-0.01%
|
$1,010
$10.4 P/Share
|